Predictive
Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”)
to personalized medicine and drug discovery, today announced its recent receipt
of notification (the “Notification Letter on Compliance”) from the Listing Qualifications
Department of the Nasdaq Stock Market Inc. (the “Nasdaq”) that indicates
Predictive Oncology has regained compliance with the minimum bid price
requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the
“Minimum Bid Price Requirement”). Per the update, Predictive Oncology received,
on November 16, 2018, notification from the Nasdaq (the “Notification Letter on
Deficiency”) indicating that the closing bid price per share had been below
$1.00 for a period of 30 Consecutive business days and that the Company did not
meet the Minimum Price Bid Requirement. The Notification Letter on Deficiency
stated that if, at any time during the Compliance Period, the closing bid price
per share is at least $1.00 for a minimum of 10 consecutive business days,
Nasdaq will provide the Company a written confirmation of compliance and the
matter will be closed. According to the Notification Letter on Compliance,
Nasdaq staff has determined that for 10 consecutive business days, beginning
October 29, 2019 through November 11, 2019, the closing bid price of POAI’s
common stock has been at $1.00 per share or greater, and the Company has
regained compliance with the Minimum Bid Price Requirement, and the matter is
now closed.
To view the full press release, visit http://ibn.fm/EfINN
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through five
segments (Domestic, International, Clinical, CRO and DCHIP), which contain four
subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe.
Helomics applies artificial intelligence to its rich data gathered from patient
tumors to both personalize cancer therapies for patients and drive the
development of new targeted therapies in collaborations with pharmaceutical
companies. Helomics’ CLIA-certified lab provides clinical testing that assists
oncologists in individualizing patient treatment decisions, by providing an
evidence-based roadmap for therapy. In addition to its proprietary precision
oncology platform, Helomics offers boutique CRO services that leverage its
TruTumor(TM), patient-derived tumor models coupled to a wide range of
multi-omics assays (genomics, proteomics and biochemical), and an AI-powered
proprietary bioinformatics platform (D- CHIP) to provide a tailored solution to
its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is
developing a new rapid approach to growing tumors in the laboratory, which
essentially “fools” cancer cells into thinking they are still growing inside a
patient. Its proprietary Oncology Discovery Technology Platform kits will
assist researchers and clinicians to identify which cancer cells bind to
specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’
Oncology Capture Technology Platforms which isolate and help categorize an
individual patient’s heterogeneous tumor samples to enable the development of
patient specific treatment options. Helomics and TumorGenesis are focused on
ovarian cancer. Predictive Oncology’s Skyline Medical division markets its
patented and FDA cleared STREAMWAY System, which automates the collection,
measurement and disposal of waste fluid, including blood, irrigation fluid and
others, within a medical facility, through both domestic and international
divisions. The company has achieved sales in five of the seven continents
through both direct sales and distributor partners. For more information,
please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
